BioSpace News Archive

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former CEO of Celgene Corporation, Mark Alles, to its Board of Directors effective January 1, 2022.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market open on Thursday, January 6, 2022.

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company appointed Mr. Baochang Liu as its Chief Operating Officer, effective December 1, 2021.

IBEX Technologies Inc. reported its financial results for the three months ended October 31, 2021.

Calliditas Therapeutics AB announced that the US Food and Drug Administration has approved TARPEYO delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5g/g.

Immix Biopharma, Inc. announced the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $21,000,000 before deducting underwriting discounts, commissions and offering expenses.

Bionique Testing Laboratories LLC, a global leader in mycoplasma testing services for the biologics and life- sciences industries, announced that it has been 100% acquired by a subsidiary of Japan- based healthcare pioneer Asahi Kasei Medical Co., Ltd.

Rakuten Medical, Inc announced that the U.S. Food and Drug Administration has accepted the company’s Investigational New Drug application to begin clinical studies of RM-1995 photoimmunotherapy in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma.

Artax Biopharma, Inc., today announces first-in-human dosing in a Phase 1 clinical trial for AX-158, the Company’s first-in-class oral small molecule immunomodulator. AX-158 is the Company’s first oral small molecule immunomodulating agent to enter clinical development for the treatment of T Cell-mediated diseases.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Keith W. Ward, PhD, to its board of directors and promoted Tu Diep, MSc to Chief Development Officer, effective immediately.